Monte Rosa Hits The Heights With $96m Cash Hike
Formed by Versant And Two UK Cancer Drug Discovery Institutions
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.
